PCI Pharma Services completes biotech Center of Excellence

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

In addition, the company has confirmed significant new investments to expand its global packaging capabilities for biologic drug products at its operations in Ireland, complementing existing capabilities in the UK and Germany.

These investments will provide customers with global packaging solutions for their biologics and injectable drug products to meet growing market demands.

With worldwide forecasts suggesting strong growth for biologics during the next few years, the company has said it wants to "stay on top" of this trend.

"We have already secured projects from numerous global biopharmaceutical customers that will benefit from the new expansion, which is a reflection of the market demand,” said Salim Haffar, CEO, PCI Pharma Services.

The recent investments include partnerships with leading suppliers such as Dividella, groninger, Marchesini Group and Syntegon (formerly Bosch Packaging Technology) to provide state-of-the-art equipment for pre-filled syringe, auto-injector and vial packaging and the latest serialization technology.

The expansions also include increasing high-speed automatic syringe assembly and labeling, vial labeling and cartoning, and auto-injector assembly – allowing for greater flexibility in serving customers across their supply-chain requirements.

In addition to building out existing cold storage capabilities and leading-edge manufacturing suites, PCI will continue to offer innovative design teams to help address the packaging challenges often presented by biologic products.